Publication:
How does usage of serotonin noradrenaline reuptake inhibitors affect intraocular pressure in depression patients?

dc.contributor.authorYener, Neslihan Parmak
dc.contributor.authorKılınçel, Oğuzhan
dc.contributor.authorGündüz, Cem
dc.contributor.buuauthorGündüz, Gamze Uçan
dc.contributor.departmentTıp Fakültesi
dc.contributor.departmentGöz Hastalıkları Ana Bilim Dalı
dc.contributor.researcheridAAH-6661-2021
dc.contributor.scopusid57204236887
dc.date.accessioned2023-11-03T09:59:12Z
dc.date.available2023-11-03T09:59:12Z
dc.date.issued2018-05
dc.description.abstractPurpose: To evaluate anterior segment parameters and intraocular pressure (IOP) modifications in patients using serotonin noradrenaline reuptake inhibitors (SNRIs) due to major depressive disorder. Methods: This cross-sectional study included 170 eyes of 85 subjects. All subjects were divided into three groups: group 1 included 44 healthy control subjects, group 2 included 22 patients receiving antidepressants for 1 week to 6 months, and group 3 included 19 patients receiving antidepressants for >6 months. All subjects underwent a detailed ophthalmologic examination, including gonioscopy. Anterior segments of all subjects were evaluated with the Scheimpflug system and pupil diameter (PD), central corneal thickness, anterior chamber depth (ACD), anterior chamber volume, and anterior chamber angle (ACA) measurements were enrolled. Results: The median IOP was significantly lower in patients using antidepressants [16.0 (11.0-21.0) mmHg] than the control group [17.5 (12.0-21.0) mmHg] (P=0.041). The PD was significantly larger in patients using antidepressants [3.56 (2.29-5.60) mm] than the control group [2.95 (2.00-4.40) mm] (P=0.000). In the study group, PD was also significantly larger in patients using SNRIs for 6 months [3.67 (2.38-5.08) mm] than <6 months [3.31 (2.29-5.60) mm] (P=0.000). The median ACD was significantly lower in patients using antidepressants for 6 months [3.21 (2.52-4.06) mm] than the control group [3.44 (2.63-4.29) mm] (P=0.000). ACAs were measured between 25 degrees and 55 degrees by Scheimpflug imaging. Conclusions: Treatment of SNRIs causes mydriasis and decrease in width of ACD. These changes may not increase IOP as long as the patient has an open angle. SNRIs lead to decrease in IOP particularly in long-term usage.
dc.identifier.citationGündüz, G. U. vd. (2018). ''How does usage of serotonin noradrenaline reuptake inhibitors affect intraocular pressure in depression patients?''. Journal of Ocular Pharmacology and Therapeutics, 34(4), 354-359.
dc.identifier.endpage359
dc.identifier.issn1080-7683
dc.identifier.issn1557-7732
dc.identifier.issue4
dc.identifier.pubmed29446702
dc.identifier.scopus2-s2.0-85046906129
dc.identifier.startpage354
dc.identifier.urihttps://doi.org/10.1089/jop.2017.0133
dc.identifier.urihttps://www.liebertpub.com/doi/10.1089/jop.2017.0133
dc.identifier.urihttp://hdl.handle.net/11452/34774
dc.identifier.volume34
dc.identifier.wos000425183200001
dc.indexed.wosSCIE
dc.language.isoen
dc.publisherMary Ann Liebert
dc.relation.collaborationSanayi
dc.relation.journalJournal of Ocular Pharmacology and Therapeutics
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectOphthalmology
dc.subjectPharmacology & pharmacy
dc.subjectAnterior segment parameters
dc.subjectIntraocular pressure
dc.subjectSerotonin noradrenaline reuptake inhibitors
dc.subjectAngle-closure glaucoma
dc.subjectVenlafaxine
dc.subjectMechanisms
dc.subjectExpression
dc.subjectPotent
dc.subjectAgents
dc.subject.emtreeDuloxetine
dc.subject.emtreeSerotonin noradrenalin reuptake inhibitor
dc.subject.emtreeVenlafaxine
dc.subject.emtreeAntidepressant agent
dc.subject.emtreeDuloxetine
dc.subject.emtreeSerotonin noradrenalin reuptake inhibitor
dc.subject.emtreeVenlafaxine
dc.subject.emtreeAdult
dc.subject.emtreeAnterior chamber volume
dc.subject.emtreeAnterior eye chamber angle
dc.subject.emtreeAnterior eye chamber depth
dc.subject.emtreeArticle
dc.subject.emtreeCentral corneal thickness
dc.subject.emtreeClinical evaluation
dc.subject.emtreeControlled study
dc.subject.emtreeCross-sectional study
dc.subject.emtreeDrug effect
dc.subject.emtreeFemale
dc.subject.emtreeGonioscopy
dc.subject.emtreeHuman
dc.subject.emtreeIntraocular pressure
dc.subject.emtreeMajor clinical study
dc.subject.emtreeMajor depression
dc.subject.emtreeMale
dc.subject.emtreeOphthalmology
dc.subject.emtreePsychopharmacotherapy
dc.subject.emtreePupil
dc.subject.emtreeVisual system parameters
dc.subject.emtreeAdolescent
dc.subject.emtreeDrug effects
dc.subject.emtreeIntraocular pressure
dc.subject.emtreeMajor depression
dc.subject.emtreeMiddle aged
dc.subject.emtreePathology
dc.subject.emtreeYoung adult
dc.subject.meshAdolescent
dc.subject.meshAdult
dc.subject.meshAntidepressive agents
dc.subject.meshCross-sectional studies
dc.subject.meshDepressive disorder, major
dc.subject.meshDuloxetine hydrochloride
dc.subject.meshFemale
dc.subject.meshHumans
dc.subject.meshIntraocular pressure
dc.subject.meshMale
dc.subject.meshMiddle aged
dc.subject.meshSerotonin and noradrenaline reuptake inhibitors
dc.subject.meshVenlafaxine hydrochloride
dc.subject.meshYoung adult
dc.subject.scopusBilateral; Angle Closure Glaucoma; Topiramate
dc.subject.wosOphthalmology
dc.subject.wosPharmacology & pharmacy
dc.titleHow does usage of serotonin noradrenaline reuptake inhibitors affect intraocular pressure in depression patients?
dc.typeArticle
dc.wos.quartileQ3
dspace.entity.typePublication
local.contributor.departmentTıp Fakültesi/Göz Hastalıkları Ana Bilim Dalı
local.indexed.atScopus
local.indexed.atWOS

Files

License bundle

Now showing 1 - 1 of 1
Placeholder
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description: